Johnson & Johnson $JNJ Shares Sold by Banco Santander S.A.

Banco Santander S.A. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 7.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,632 shares of the company’s stock after selling 4,391 shares during the quarter. Banco Santander S.A.’s holdings in Johnson & Johnson were worth $8,345,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Greenup Street Wealth Management LLC boosted its stake in Johnson & Johnson by 3.1% during the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after purchasing an additional 60 shares in the last quarter. Ellis Investment Partners LLC lifted its holdings in shares of Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after purchasing an additional 62 shares in the last quarter. Cypress Wealth Services LLC lifted its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after purchasing an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN raised its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after acquiring an additional 64 shares in the last quarter. Finally, Global Strategic Investment Solutions LLC raised its holdings in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Bank of America lifted their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. HSBC boosted their price target on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, UBS Group lifted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Performance

JNJ stock opened at $190.31 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a 50 day moving average price of $182.54 and a 200 day moving average price of $166.65. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The stock has a market capitalization of $458.50 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.